Month: April 2022

Posted on

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022

  • Year-over-year revenue grows 12%, operating profit up 5%, non-GAAP operating profit up 5%

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) — ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2022.

Third Quarter 2022 Highlights
All comparisons are to the prior year period

  • Revenue increased by 12% to $864.5 million; up 14% on a constant currency basis
  • Gross margin contracted 140 bps to 56.8%; non-GAAP gross margin contracted 150 bps to 58.1%
  • Income from operations increased 5%; non-GAAP operating profit up 5%
  • Diluted earnings per share of $1.22; non-GAAP diluted earnings per share of $1.32

“Our third-quarter results reflect strong performance across our business, resulting in double-digit top-line revenue growth including extraordinary demand in our sleep and respiratory care business segment as well as solid high-single-digit growth in our software-as-a-service segment,” said Mick Farrell, ResMed CEO. “I am proud of our global team’s ability to pivot and drive continued growth while ongoing supply chain disruptions and a competitor’s recall continue to limit our ability to meet the incredible demand for our products. We remain focused on delivering products, software, and services for patients, working closely with our supply chain partners as well as physicians, providers, and beyond, to prioritize care for patients who most need it.

“While the current industry and macroeconomic environment remain uncertain, our long-term strategy allows us to keep our focus on helping 250 million lives in 2025. Our end-market demand from patients and providers remains strong, and our digital health technologies continue to deliver value. We are supporting patients with the world-leading portfolio of sleep apnea therapy, respiratory care therapy, and digital health solutions they need, as we deliver value for all of our customers.”

Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts

Three Months Ended
March 31,
2022		 March 31,
2021		 % Change Constant
Currency (A)
Revenue $ 864.5 $ 768.8 12 % 14 %
Gross margin (B) 56.8 % 58.2 % (2 )
Non-GAAP gross margin (B) 58.1 % 59.6 % (3 )
Selling, general, and administrative expenses 182.4 160.4 14 17
Research and development expenses 66.8 55.9 19 22
Income from operations 234.3 223.4 5
Non-GAAP income from operations (B) 253.0 241.8 5
Net income (loss) 179.0 (78.5 ) NM
Non-GAAP net income (B) 193.3 190.4 2
Diluted earnings (loss) per share $ 1.22 $ (0.54 ) NM
Non-GAAP diluted earnings per share (B) $ 1.32 $ 1.30 2

NM        Not meaningful

Nine Months Ended
March 31,
2022		 March 31,
2021		 % Change Constant
Currency (A)
Revenue $ 2,663.4 $ 2,320.7 15 % 15 %
Gross margin (B) 56.4 % 58.1 % (3 )
Non-GAAP gross margin (B) 57.6 % 59.8 % (4 )
Selling, general, and administrative expenses 544.5 488.9 11 13
Research and development expenses 189.3 165.4 14 15
Income from operations 744.9 662.0 13
Non-GAAP income from operations (B) 801.3 733.4 9
Net income 584.4 279.4 109
Non-GAAP net income (B) 631.5 582.2 8
Diluted earnings per share $ 3.97 $ 1.91 108
Non-GAAP diluted earnings per share (B) $ 4.30 $ 3.98 8

(A)     In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)     See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of Third Quarter Results
All comparisons are to the prior year period unless otherwise noted

  • Revenue grew by 14 percent on a constant currency basis, driven by increased demand for our sleep and respiratory care devices and increased demand following a recent product recall by one of our competitors.
    • Revenue in the U.S., Canada, and Latin America, excluding software-as-a-service, grew by 18 percent, primarily due to the factors discussed above and recovery of core sleep patient flow that was previously impacted by COVID-19.
    • Revenue in Europe, Asia, and other markets grew by 11 percent on a constant currency basis, primarily due to the factors discussed above.
    • Software-as-a-service revenue increased by 8 percent, due to continued growth in our Durable Medical Equipment category and stabilizing patient flow in out-of-hospital care settings.
  • Gross margin decreased by 140 basis points and non-GAAP gross margin decreased by 150 basis points, mainly due to higher freight and manufacturing costs, partially offset by favorable product mix changes and increase in average selling prices.
  • Selling, general, and administrative expenses increased by 17 percent on a constant currency basis. SG&A expenses increased to 21.1 percent of revenue in the quarter, compared with 20.9 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to increases in employee-related expenses.
  • Income from operations increased by 5 percent and non-GAAP income from operations increased by 5 percent.
  • Net income for the quarter was $179.0 million and diluted earnings per share was $1.22. Non-GAAP net income grew by 2 percent and non-GAAP diluted earnings per share grew by 2 percent, predominantly attributable to strong sales, partially offset by higher operating expenses.
  • Operating cash flow for the quarter was $117.4 million, compared to net income in the current quarter of $179.0 million and non-GAAP net income of $193.3 million. During the quarter we paid $61.4 million in dividends.

Other Business and Operational Highlights

  • Announced appointment of Urvashi Tyagi as new Chief Technology Officer and Bobby Ghoshal transitions to be President of ResMed’s software-as-a-service business segment full-time. Tyagi leads ResMed’s digital health technology team, driving innovation and adoption of world-leading cloud-based digital health platforms and investments in emerging technologies.
  • Published 2022 Global Sleep Surveys as part of National Sleep Awareness Week (March 13-19) and World Sleep Day (March 18). The surveys, conducted in the first quarter of the calendar year, asked nearly 25,000 respondents in 12 countries what’s keeping them up at night; the results aim to build awareness of the critical role good sleep plays in physical and mental health.

Dividend program
The ResMed board of directors today declared a quarterly cash dividend of $0.42 per share. The dividend will have a record date of May 12, 2022, payable on June 16, 2022. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 11, 2022, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 11, 2022, through May 12, 2022, inclusive.

Webcast details
ResMed will discuss its third-quarter fiscal year 2022 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2022 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13727876. The telephone replay will be available until May 12, 2022.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)

Three Months Ended Nine Months Ended
March 31,
2022		 March 31,
2021		 March 31,
2022		 March 31,
2021
Net revenue $ 864,500 $ 768,767 $ 2,663,390 $ 2,320,722
Cost of sales 362,321 310,585 1,128,314 933,021
Amortization of acquired intangibles (1) 10,982 10,924 33,271 34,066
Restructuring—cost of sales (1) — — — 5,232
Total cost of sales $ 373,303 $ 321,509 $ 1,161,585 $ 972,319
Gross profit $ 491,197 $ 447,258 $ 1,501,805 $ 1,348,403
Selling, general, and administrative 182,401 160,446 544,483 488,904
Research and development 66,801 55,941 189,258 165,409
Amortization of acquired intangibles (1) 7,730 7,445 23,175 23,377
Restructuring—operating expenses (1) — — — 8,673
Total operating expenses $ 256,932 $ 223,832 $ 756,916 $ 686,363
Income from operations 234,265 223,426 744,889 662,040
Other income (expenses), net:
Interest income (expense), net $ (5,462 ) $ (5,823 ) $ (16,770 ) $ (18,341 )
Loss attributable to equity method investments (2,627 ) (4,969 ) (5,927 ) (9,895 )
Gain (loss) on equity investments (1,735 ) 4,666 (527 ) 9,442
Other, net 1,878 705 729 1,205
Total other income (expenses), net (7,946 ) (5,421 ) (22,495 ) (17,589 )
Income before income taxes $ 226,319 $ 218,005 $ 722,394 $ 644,451
Income taxes 47,307 296,486 138,018 365,046
Net income (loss) $ 179,012 $ (78,481 ) $ 584,376 $ 279,405
Basic earnings per share $ 1.22 $ (0.54 ) $ 4.00 $ 1.92
Diluted earnings per share $ 1.22 $ (0.54 ) $ 3.97 $ 1.91
Non-GAAP diluted earnings per share (1) $ 1.32 $ 1.30 $ 4.30 $ 3.98
Basic shares outstanding 146,240 145,513 145,969 145,217
Diluted shares outstanding 146,962 145,513 147,034 146,394

(1)    See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)

March 31,
2022		 June 30,
2021
ASSETS
Current assets:
Cash and cash equivalents $ 201,769 $ 295,278
Accounts receivable, net 508,580 614,292
Inventories 664,943 457,033
Prepayments and other current assets 329,008 208,154
Total current assets $ 1,704,300 $ 1,574,757
Non-current assets:
Property, plant, and equipment, net $ 513,250 $ 463,490
Operating lease right-of-use assets 141,173 128,575
Goodwill and other intangibles, net 2,302,301 2,320,483
Deferred income taxes and other non-current assets 244,240 240,820
Total non-current assets $ 3,200,964 $ 3,153,368
Total assets $ 4,905,264 $ 4,728,125
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities:
Accounts payable $ 149,797 $ 138,008
Accrued expenses 326,276 320,599
Operating lease liabilities, current 24,130 23,585
Deferred revenue 112,449 109,611
Income taxes payable 42,646 307,963
Short-term debt 11,967 12,000
Total current liabilities $ 667,265 $ 911,766
Non-current liabilities:
Deferred revenue $ 94,094 $ 91,496
Deferred income taxes 10,711 11,319
Operating lease liabilities, non-current 127,254 114,779
Other long-term liabilities 5,103 6,802
Long-term debt 668,735 643,351
Long-term income taxes payable 53,298 62,933
Total non-current liabilities $ 959,195 $ 930,680
Total liabilities $ 1,626,460 $ 1,842,446
STOCKHOLDERS’ EQUITY:
Common stock $ 585 $ 583
Additional paid-in capital 1,645,453 1,622,199
Retained earnings 3,480,163 3,079,640
Treasury stock (1,623,256 ) (1,623,256 )
Accumulated other comprehensive income (224,141 ) (193,487 )
Total stockholders’ equity $ 3,278,804 $ 2,885,679
Total liabilities and stockholders’ equity $ 4,905,264 $ 4,728,125

Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)

Nine months ended
March 31,
2022		 March 31,
2021
Cash flows from operating activities:
Net income $ 584,376 $ 279,405
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization 122,198 120,034
Amortization of right-of-use assets 26,636 25,805
Stock-based compensation costs 49,265 47,032
Loss attributable to equity method investments 5,927 9,895
(Gain) loss on equity investment 527 (9,442 )
Restructuring expenses — 8,673
Changes in operating assets and liabilities:
Accounts receivable, net 98,158 (39,899 )
Inventories, net (209,476 ) (48,393 )
Prepaid expenses, net deferred income taxes and other current assets (127,977 ) (41,036 )
Accounts payable, accrued expenses, income taxes payable and other (277,973 ) 158,119
Net cash (used in) / provided by operating activities $ 271,661 $ 510,193
Cash flows from investing activities:
Purchases of property, plant, and equipment (106,192 ) (74,805 )
Patent registration and acquisition costs (17,449 ) (11,149 )
Business acquisitions, net of cash acquired (35,915 ) (30,704 )
Purchases of investments (16,614 ) (20,038 )
Proceeds from sale of investment 6,802 —
(Payments) / proceeds on maturity of foreign currency contracts (5,309 ) 26,306
Net cash used in investing activities $ (174,677 ) $ (110,390 )
Cash flows from financing activities:
Proceeds from issuance of common stock, net 26,269 18,759
Taxes paid related to net share settlement of equity awards (52,278 ) (49,938 )
Payments of business combination contingent consideration — (3,500 )
Proceeds from borrowings, net of borrowing costs 160,000 90,000
Repayment of borrowings (136,000 ) (536,000 )
Dividends paid (183,853 ) (169,917 )
Net cash (used in) / provided by financing activities $ (185,862 ) $ (650,596 )
Effect of exchange rate changes on cash $ (4,631 ) $ 18,272
Net increase / (decrease) in cash and cash equivalents (93,509 ) (232,521 )
Cash and cash equivalents at beginning of period 295,278 463,156
Cash and cash equivalents at end of period $ 201,769 $ 230,635

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:

Three Months Ended Nine Months Ended
March 31, 2022 March 31, 2021 March 31, 2022 March 31, 2021
Revenue $ 864,500 $ 768,767 $ 2,663,390 $ 2,320,722
GAAP Cost of sales $ 373,303 $ 321,509 $ 1,161,585 $ 972,319
Less: Amortization of acquired intangibles (A) (10,982 ) (10,924 ) (33,271 ) (34,066 )
Less: Restructuring—cost of sales (A) — — — (5,232 )
Non-GAAP cost of sales $ 362,321 $ 310,585 $ 1,128,314 $ 933,021
GAAP gross profit $ 491,197 $ 447,258 $ 1,501,805 $ 1,348,403
GAAP gross margin 56.8 % 58.2 % 56.4 % 58.1 %
Non-GAAP gross profit $ 502,179 $ 458,182 $ 1,535,076 $ 1,387,701
Non-GAAP gross margin 58.1 % 59.6 % 57.6 % 59.8 %

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

Three Months Ended Nine Months Ended
March 31,
2022		 March 31,
2021		 March 31,
2022		 March 31,
2021
GAAP income from operations $ 234,265 $ 223,426 $ 744,889 $ 662,040
Amortization of acquired intangibles—cost of sales (A) 10,982 10,924 33,271 34,066
Amortization of acquired intangibles—operating expenses (A) 7,730 7,445 23,175 23,377
Restructuring—cost of sales (A) — — — 5,232
Restructuring—operating expenses (A) — — — 8,673
Non-GAAP income from operations $ 252,977 $ 241,795 $ 801,335 $ 733,388

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

Three Months Ended Nine Months Ended
March 31,
2022		 March 31,
2021		 March 31,
2022		 March 31,
2021
GAAP net income (loss) $ 179,012 $ (78,481 ) $ 584,376 $ 279,405
Amortization of acquired intangibles—cost of sales, net of tax(A) 8,374 8,395 25,373 26,136
Amortization of acquired intangibles—operating expenses, net of tax(A) 5,894 5,721 17,673 17,936
Reserve for disputed tax position(A) — 254,776 4,111 254,776
Restructuring—cost of sales, net of tax(A) — — — 4,663
Restructuring—operating expenses, net of tax(A) — — — 7,730
(Gain) loss on equity investments(A) — — — (8,476 )
Non-GAAP net income(A) $ 193,280 $ 190,411 $ 631,533 $ 582,170
GAAP diluted shares outstanding 146,962 145,513 147,034 146,394
Anti-dilutive shares excluded from GAAP — 858 — —
Non-GAAP diluted shares outstanding 146,962 146,371 147,034 146,394
GAAP diluted earnings (loss) per share $ 1.22 $ (0.54 ) $ 3.97 $ 1.91
Non-GAAP diluted earnings per share(A) $ 1.32 $ 1.30 $ 4.30 $ 3.98

(A)     ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)

Three Months Ended
March 31,
2022		 (A) March 31,
2021		 (A) % Change Constant
Currency (B)
U.S., Canada, and Latin America
Devices $ 250.8 $ 192.9 30 %
Masks and other 224.7 210.0 7
Total Sleep and Respiratory Care $ 475.4 $ 402.9 18
Software as a Service 101.1 93.8 8
Total $ 576.6 $ 496.7 16
Combined Europe, Asia, and other markets
Devices $ 182.3 $ 172.8 5 % 10 %
Masks and other 105.6 99.2 6 13
Total Sleep and Respiratory Care $ 287.9 $ 272.1 6 11
Global revenue
Devices $ 433.1 $ 365.7 18 % 21 %
Masks and other 330.3 309.2 7 9
Total Sleep and Respiratory Care $ 763.4 $ 674.9 13 15
Software as a Service 101.1 93.8 8 8
Total $ 864.5 $ 768.8 12 14
Nine Months Ended
March 31,
2022		 (A) March 31,
2021		 (A) %
Change		 Constant
Currency (B)
U.S., Canada, and Latin America
Devices $ 771.5 $ 595.3 30 %
Masks and other 681.8 637.5 7
Total Sleep and Respiratory Care $ 1,453.3 $ 1,232.8 18
Software as a Service 297.7 277.8 7
Total $ 1,751.0 $ 1,510.6 16
Combined Europe, Asia, and other markets
Devices $ 608.3 $ 536.9 13 % 15 %
Masks and other 304.2 273.3 11 14
Total Sleep and Respiratory Care $ 912.4 $ 810.1 13 15
Global revenue
Devices $ 1,379.7 $ 1,132.1 22 % 23 %
Masks and other 986.0 910.8 8 9
Total Sleep and Respiratory Care $ 2,365.7 $ 2,042.9 16 16
Software as a Service 297.7 277.8 7 7
Total $ 2,663.4 $ 2,320.7 15 15

(A)    Totals and subtotals may not add due to rounding.

(B)    In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

For investors For media
Amy Wakeham Jayme Rubenstein
+1 858-836-5000 +1 858-836-6798
investorrelations@resmed.com news@resmed.com
Posted on

World’s First DDoS Risk Assessment Product – Israeli Cybersecurity Company MazeBolt Announces $10 Million in Funding

MazeBolt RADAR

MazeBolt RADAR

RAMAT GAN, Israel, April 28, 2022 (GLOBE NEWSWIRE) — MazeBolt Technologies, an Israeli cybersecurity firm transforming DDoS mitigation, today announced the completion of a $10,000,000 existing shareholders equity financing. MazeBolt also announced today the addition of two leaders in the cybersecurity field to its Advisory Board, Glenn Gerstell, former General Counsel of the US National Security Agency (“NSA”), and Amichai Shulman, former founder and CTO of IMPERVA.

MazeBolt RADAR is a patented technology which dramatically reduces DDoS risk, in most cases by orders of magnitude. Commercially introduced last year – after more than three years of development and BETA testing – RADAR is based on a totally new concept of continuously testing the entire attack surface of networks and services for DDoS vulnerabilities, without any disruption to production availability. Once identified, all existing vulnerabilities can then be pre-emptively corrected and the fixes validated, again without disruption. By enabling these first-ever capabilities, the addition of MazeBolt RADAR now enables a transformation of DDoS mitigation from requiring reactive manual recovery to near-perfect automatic mitigation of all DDoS attacks for any web-facing network, regardless of the DDoS mitigation platform it is in use with.

As a new product in a very “noisy” marketplace, Mr. Andriani CEO & Founder of MazeBolt stated, “Our immediate key challenge is to bring to the attention of cybersecurity decision-makers the fact that this first-of-a-kind product is now available and has been extensively validated in commercial use across multiple industries and environments. During 2021, our first year of full commercialization, we were pleased to see that every completed proof of concept resulted in a new RADAR customer. Furthermore, to date, no customer that fully implemented MazeBolt RADAR has suffered a successful DDoS attack.”

Press Contact: info@mazebolt.com

Related Images

Image 1: MazeBolt RADAR

This content was issued through the press release distribution service at Newswire.com.

Attachment

Posted on

Delphix เร่งการเติบโตและความสามารถในการทำกำไรเป็นปีที่สองติดต่อกัน

ความปลอดภัยของข้อมูลและการปฏิบัติตามข้อกำหนดผลักดันให้มีการใช้งานแพลตฟอร์มการจัดการข้อมูลการทดสอบ Delphix DevOps เพิ่มขึ้นอย่างรวดเร็ว

เรดวูดซิตี้ แคลิฟอร์เนีย, April 29, 2022 (GLOBE NEWSWIRE) —  Delphix ผู้นำอุตสาหกรรมในการจัดการข้อมูลการทดสอบ DevOps (TDM) ประกาศปิดปีงบประมาณ 2022 ด้วยการเติบโตของรายได้และความสามารถในการทำกำไรในระดับที่รวดเร็วเป็นปีที่สองติดต่อกัน โดยมีรายได้ประจำประจำปี (ARR) มากกว่า 100 ล้านเหรียญสหรัฐ

ด้วยกิจกรรมที่เพิ่มขึ้นจากประเทศที่เป็นศัตรูและแก๊งแรนซัมแวร์ บริษัทต่าง ๆ ทั่วโลกจึงต้องการโซลูชันในการทำให้ข้อมูลทดสอบเป็นอัตโนมัติและมีการรักษาความปลอดภัยสำหรับแอปพลิเคชันระดับองค์กร ด้วยเหตุนี้ ทำให้บริษัทมีการเติบโตของฐานลูกค้าองค์กรขนาดใหญ่ที่เติบโตเร็วขึ้น 36% เมื่อเทียบเป็นรายปี โดยได้แรงหนุนจากความเสี่ยงด้านข้อมูลที่เพิ่มขึ้น

การเติบโตของ Delphix เกิดขึ้นเนื่องจากบริษัทต่าง ๆ ทั่วโลกยังคงลงทุนในโซลูชัน DevOps ที่เป็นนวัตกรรมใหม่ๆ เพื่อเร่งการส่งมอบแอปพลิเคชัน ปรับปรุงโครงสร้างพื้นฐานแบบเดิมให้ทันสมัย และเคลื่อนย้ายแอปพลิเคชันต่าง ๆ ไปทั่วมัลติคลาวด์ Delphix นำเสนอแพลตฟอร์ม DevOps TDM เพียงแพลตฟอร์มเดียวที่ส่งมอบข้อมูลที่ปลอดภัยและเป็นไปตามข้อกำหนดสำหรับการทดสอบและการพัฒนาโดยอัตโนมัติ ทำให้สามารถสร้างสรรค์นวัตกรรมได้เร็วขึ้นถึง 10 เท่า

Jedidiah Yueh ผู้ก่อตั้งและซีอีโอของ Delphix กล่าวว่า “แอปพลิเคชันระดับองค์กรล้วนต้องการข้อมูลทดสอบเพื่อการเผยแพร่ที่รวดเร็วและมีคุณภาพ” “แต่ปกติแล้วข้อมูลการทดสอบจะช้า ซับซ้อน และเต็มไปด้วยความเสี่ยง Delphix ช่วยให้บริษัทต่างๆ เช่น Banco Carrefour, The University of Manchester และ BNP Paribas เปิดตัวแอปพลิเคชันต่างๆ ได้อย่างรวดเร็ว พร้อมทั้งได้ปรับปรุงความปลอดภัยและการปฏิบัติตามข้อกำหนดของข้อมูลไปด้วยกัน”

Banco Carrefour ในบราซิลใช้แพลตฟอร์มข้อมูล Delphix DevOps เพื่อเร่งการเปิดตัวแอปพลิเคชัน พร้อมทั้งได้มีการรับรองความปลอดภัยของข้อมูลและการปฏิบัติตามกฎระเบียบด้านความเป็นส่วนตัวไปด้วยกัน เช่น กฎหมายคุ้มครองข้อมูลทั่วไปของบราซิล (LGPD) Delphix เพิ่มขีดความสามารถให้ทีมพัฒนาด้วยความพร้อมใช้งานของข้อมูลที่เร็วขึ้นถึง 320 เท่าสำหรับการรายงานและการวิเคราะห์ทางการเงิน ช่วยให้ออกแอปพลิเคชันได้เร็วขึ้น และช่วยประหยัดพื้นที่จัดเก็บได้ถึง 70%

Delphix นำเสนอแพลตฟอร์มข้อมูล API ซึ่งเป็นนวัตกรรมใหม่ที่เปลี่ยนการส่งมอบแอปพลิเคชันด้วยการควบคุมข้อมูลที่ครอบคลุม Delphix ช่วยให้นักพัฒนาซอฟต์แวร์สร้างสรรค์สิ่งใหม่ ๆ ได้เร็วขึ้น ในขณะที่ลดความเสี่ยงในการปฏิบัติตามข้อกำหนดและความปลอดภัย โดยใช้การส่งข้อมูลแบบอัตโนมัติในสภาพแวดล้อมของการทดสอบ

Delphix ยังช่วยให้บริษัทกู้คืนข้อมูลจากการโจมตีของแรนซัมแวร์ได้เร็วขึ้น ด้วยการปกป้องข้อมูลอย่างต่อเนื่องและทำให้ข้อมูลในอดีตไม่เปลี่ยนแปลง

Yves Caseau ประธานเจ้าหน้าที่ฝ่ายดิจิทัลและสารสนเทศของกลุ่มบริษัท Michelin กล่าวว่า “เราเลือก Delphix เพราะเราชอบเทคโนโลยีที่ใช้เป็นเครื่องมือในการย้ายข้อมูลอย่างมีประสิทธิภาพจากที่หนึ่งไปยังอีกที่หนึ่ง เพื่อนำไปสร้างใหม่ และเพื่อเดินทางสู่อดีต” “หากเราดูสิ่งที่เราทำไปแล้ว เราใช้ Delphix เพื่อย้ายข้อมูลจากเซิร์ฟเวอร์ Exadata รุ่นเก่าไปยังเซิร์ฟเวอร์ Linux ของชุมชนเพื่อเพิ่มความสามารถในการปรับขนาดและใช้ต้นทุนต่ำลง”

Caseau กล่าวเสริมว่า “เรายังใช้ Delphix ในการเร่งนวัตกรรมและตั้งค่าสภาพแวดล้อมการทดสอบและการพัฒนาใหม่ให้เร็วขึ้น เราสามารถรับข้อมูลที่เหมาะสมทั้งหมดได้อย่างรวดเร็วด้วยพอยน์เตอร์เพียงไม่กี่ตัวและด้วยการคลิกเพียงแค่ไม่กี่ครั้ง อีกทั้งยังมีการถ่ายโอนข้อมูลเสมือนเมื่อเทียบกับข้อมูลที่มีอยู่จริง”

การจัดการข้อมูลการทดสอบเป็นองค์ประกอบที่สำคัญของการพัฒนาแอปพลิเคชัน แต่มักจะช้าและต้องทำด้วยตัวเอง แพลตฟอร์มข้อมูล Delphix DevOps ช่วยให้ทีมงานสามารถสร้าง จัดการ และทำให้สภาพแวดล้อมข้อมูลบนคลาวด์แบบไฮบริดเป็นแบบอัตโนมัติ เพื่อรองรับไปป์ไลน์ CI/CD และฝึกอัลกอริทึม AI/ML

Jim Mercer ผู้อำนวยการฝ่ายวิจัยของ DevOps และ DevSecOps ที่ IDC กล่าวว่า “ข้อมูลการทดสอบที่เป็นไปตามข้อกำหนดเป็นส่วนสำคัญของ DevOps และการทำให้มั่นใจว่าการเข้าถึงข้อมูลอย่างต่อเนื่องเป็นกุญแจสำคัญสำหรับองค์กรต่างๆ ในการเร่งการส่งมอบแอปพลิเคชัน” “เนื่องจากการเปลี่ยนผ่านสู่ดิจิทัลมีความจำเป็นมากขึ้นเรื่อย ๆ สำหรับองค์กรต่างๆ เพื่อแข่งขันในตลาดปัจจุบัน เราจึงยังคงเห็นถึงความต้องการโซลูชัน TDM ที่ทันสมัยในอุตสาหกรรมต่าง ๆ”

ไฮไลท์การเติบโตของ Delphix

Delphix ยังได้แนะนำนวัตกรรมหลายอย่างในการนำเสนอผลิตภัณฑ์ของบริษัทในปีงบประมาณที่แล้ว ได่แก่:

  • ห้องนิรภัยต่อเนื่องซึ่งเป็นความสามารถเฉพาะเพื่อแรนซัมแวร์ที่ช่วยเพิ่มความสามารถในการเก็บแยกข้อมูลจากกันของแพลตฟอร์ม Delphix และเสริมความแข็งแกร่งให้กับการปกป้องข้อมูลสำหรับองค์กร
  • ความสามารถในการปฏิบัติตามข้อมูลสำหรับลูกค้า Salesforceซึ่งช่วยปกป้องความเป็นส่วนตัวและความปลอดภัยของข้อมูลให้แก่ลูกค้า Salesforce ในขณะที่ยังช่วยปลดล็อกค่าในข้อมูล Salesforce ทั่วทั้งระบบคลาวด์และศูนย์ข้อมูลภายในองค์กร
  • หอควบคุมข้อมูลซึ่งให้จุดควบคุมเพียงจุดเดียวสำหรับระบบอัตโนมัติของข้อมูลการทดสอบที่ขับเคลื่อนด้วย API ทั่วทั้งไปป์ไลน์การพัฒนาตามขนาด
  • กำบังอัลกอริธึมสำหรับการปฏิบัติตามอย่างต่อเนื่องซึ่งนำเสนออัลกอริธึมระดับแนวหน้าของอุตสาหกรรมสำหรับการปกปิดข้อมูลที่ละเอียดอ่อนพร้อมกับ SDK ทำให้อัลกอริธึมที่กำหนดเองได้นั้นสามารถพัฒนาและดำเนินการได้อย่างอัตโนมัติ
  • การรวมระบบที่รับรองโดย SAP กับ SAP NetWeaver® และ SAP S/4HANA®ซึ่งช่วยให้ธุรกิจต่างๆ ใช้ Delphix เพื่อปกปิดและส่งข้อมูล SAP เสมือนจริงที่มีประสิทธิภาพผ่าน API ได้โดยอัตโนมัติ

เกี่ยวกับ Delphix

Delphix เป็นผู้นำในระบบอุตสาหกรรมการจัดเก็บข้อมูลการทดสอบ DevOps

ธุรกิจจำเป็นต้องเปลี่ยนรูปแบบการนำส่งแอปพลิเคชัน แต่ต้องใช้ความพยายามในการปรับความเร็วให้สมดุลกับการรักษาความปลอดภัยของข้อมูลและการปฏิบัติตามข้อบังคับ แพลตฟอร์มข้อมูล DevOps ของเราทำให้การรักษาความปลอดภัยข้อมูลเป็นแบบอัตโนมัติ ในขณะที่ปรับใช้ข้อมูลทดสอบอย่างรวดเร็วเพื่อเร่งการเปิดตัวแอปพลิเคชัน ด้วย Delphix ลูกค้าสามารถปรับแอปพลิเคชันให้ทันสมัย ปรับใช้มัลติคลาวด์ บรรลุ CI/CD และกู้คืนจากเหตุการณ์หยุดทำงาน เช่น แรนซัมแวร์ได้เร็วขึ้นสูงสุดถึง 2 เท่า

บริษัทชั้นนำ เช่น Choice Hotels, Banco Carrefour และ Fannie Mae ต่างก็ใช้ Delphix เพื่อเร่งการเปลี่ยนแปลงทางดิจิทัลและเปิดใช้งานการจัดการข้อมูลแบบ Zero trust เยี่ยมชมเราได้ที่ www.delphix.com ติดตามเราได้ที่ ลิงกต์อิน หทวิตเตอร์ และ เฟซบุ๊ก 

Josh Harbert

ประธานเจ้าหน้าที่ฝ่ายการตลาด                |        Delphix

913.972.6180
Posted on

Philips successfully prices offering of Notes for EUR 2 billion

April 28, 2022

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL, OR ANY SOLICITATION OF AN OFFER TO PURCHASE, ANY SECURITIES OF PHILIPS.

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its issue of EUR 750 million fixed rate notes due 2027 (“2027 Notes”), EUR 650 million Green Innovation Notes due 2029 and EUR 600 million Sustainability Innovation Notes due 2033 (together, the “Notes”) under its European Medium Term Note (EMTN) program (the “EMTN Offering”).

The net proceeds of the Notes will be used for Eligible Projects in accordance with Philips Green and Sustainability Innovation Bond Framework and, in the case of the 2027 Notes, for general corporate purposes. Pending the full allocation of the net proceeds of the Notes, Philips intends to optimize its short-term treasury liquidity profile by applying such net proceeds towards the following liability management transactions which were announced earlier today, all of which are subject to the successful completion of the EMTN Offering:

  • A tender offer for certain series of its outstanding U.S. Dollar-denominated bonds due 2025 and 2026;
  • A tender offer for certain series of its outstanding Euro-denominated notes due 2023, 2024 and 2025 (the “Euro Tender Offer”);
  • The proposed make-whole redemption of any of the Euro-denominated notes due 2023 and 2024 that are not purchased in the Euro Tender Offer (the “Euro Make-Whole Redemption”); and
  • The proposed agreement with the relevant counterparties for early settlement of the outstanding forward contracts entered into in the third quarter of 2021 under the share buyback program for capital reduction purposes announced on July 26, 2021 (the “Early Forward Settlement”). The acquisition of 19,571,218 shares through the settlement of these forward contracts would result in the early completion of the repurchase program. Philips would then expect to cancel a total of approximately 28.3 million shares (including shares acquired through open market purchases in December 2021 and January 2022 under the aforementioned share buyback program) in the course of 2022, representing 3.3% of Philips’ currently outstanding shares.

Any decision by Philips to redeem outstanding bonds in the Euro Make-Whole Redemptions, or to complete the Early Forward Settlement, will depend on various factors at that time.

The issue price for the 2027 Notes is 99.458% with a Coupon of 1.875%, resulting in a yield of 1.990%. The issue price for the Green Innovation Notes is 99.165% with a Coupon of 2.125%, resulting in a yield of 2.248%. The issue price for the Sustainability Innovation Notes is 99.473% with a Coupon of 2.625%, resulting in a yield of 2.681%.

Settlement and issue of the Notes is scheduled for 5 May 2022. Application has been made for the Notes to be listed on the Official List of the Luxembourg Stock Exchange and to trading on the regulated market of the Luxembourg Stock Exchange.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 5977055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the EMTN Offering, the USD Tender Offer, the Euro Tender Offer, the Euro Make-Whole Redemption and the Early Forward Settlement. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Important Information
This announcement is for informational purposes only and does not constitute or form part of any offer or invitation to sell, or any solicitation of an offer to purchase, any securities of Philips.  The securities offered in the EMTN Offering have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  Neither the EMTN Offering nor the Euro Tender Offer is being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality (including, without limitation, facsimile transmission, telex, telephone, email and other forms of electronic transmission) of interstate or foreign commerce of, or any facility of a national securities exchange of, or to owners of the subject securities who are located or resident in the United States or to U.S. Persons as defined in Regulation S of the Securities Act.

In the United Kingdom, this announcement is being distributed to, and is directed at, only (a) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); or (b) high net worth companies, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Notes are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in EEA or UK.

Posted on

Bombardier to Report First Quarter 2022 Financial Results and Hold Virtual Annual and Special Meeting of Shareholders on Thursday, May 5, 2022

MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2022 on May 5, 2022. On the same day, Bombardier will hold its Annual and Special Meeting of Shareholders (“Meeting”) in a virtual format.

Quarterly Conference Call

On May 5, 2022, at 8:00 a.m. EDT, Bombardier will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the first quarter ended March 31, 2022.

A live webcast of the call and relevant financial charts will be available at https://ir.bombardier.com

Stakeholders wishing to listen to the presentation and subsequent question-and-answer period by telephone may dial one of the following conference call numbers:

In English:

Toll-free dial-in number (Canada/U.S.): 1-800-898-3989
Local dial-in number: 514-861-3304
International dial-in numbers

Participant passcode: 2230833#

In French (with translation):
Toll-free dial-in number (Canada/U.S.): 1-877-395-0279
Local dial-in number: 514-392-1587
International dial-in numbers

Participant passcode: 4427560#

Media Call

May 5, 2022, at 9:30 a.m. EDT, members of the media are invited to dial in to a short Question and Answer session following our quarterly earnings call and before the virtual Annual and Special Meeting of Shareholders. Éric Martel, President and Chief Executive Officer of Bombardier, will be available to answer your questions related to the Q1 2022 financial results.

Media who would like to attend the Q&A session are asked to RSVP by emailing heather.neale@aero.bombardier.com.

Bilingual:

Toll-free dial-in number (Canada/U.S.): 1-800-952-5114
Local dial-in number: 416-406-0743
International dial-in numbers

Participant passcode: 2423914#

Annual and Special Meeting of Shareholders

On May 5, 2022, at 10:30 a.m. EDT, Bombardier welcomes all registered shareholders and duly appointed proxyholders who wish to participate in the online Meeting to do so by joining the live webcast available at https://bombardier.com/en/agm2022. Only registered shareholders and duly appointed proxyholders will be allowed to vote and ask questions during the live Meeting. Non-registered shareholders, guests and media will be able to watch online via the live webcast available at the same link.

Instructions on how to vote and participate in the online Meeting, including submitting questions to management and to the Chairman of the Board of Directors of Bombardier, will be available on the Corporation’s website here and on the online Meeting platform. Bombardier encourages shareholders to vote and submit their proxies prior to the Meeting.

The live webcast and relevant documents for both the Annual and Special Meeting of Shareholders and the conference call will be available at https://bombardier.com/en/agm2022. A recording of the Meeting and the call will be posted on Bombardier’s website shortly after the end of the webcast.

About Bombardier
Bombardier is a global leader in aviation, focused on designing, manufacturing and servicing the world’s most exceptional business jets. Bombardier’s Challenger and Global aircraft families are renowned for their cutting-edge innovation, cabin design, performance and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals. Bombardier aircraft are also trusted around the world in special-mission roles.

Headquartered in Montréal, Québec, Bombardier operates aerostructure, assembly and completion facilities in Canada, the United States and Mexico. The company’s robust customer support network includes facilities in strategic locations in the United States and Canada, as well as in the United Kingdom, Germany, France, Switzerland, Italy, Austria, the UAE, Singapore, China and an Australian facility opening in 2022.

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, visit bombardier.com. Learn more about Bombardier’s industry-leading products and customer service network at businessaircraft.bombardier.com. Follow us on Twitter @Bombardier.

Bombardier is a registered trademark of Bombardier Inc. or its subsidiaries.

For Information

Francis Richer de La Flèche
Vice President
Financial Planning and Investor Relations
Bombardier
+514 855 5001 x13228		 Anna Cristofaro
Manager
Communications
Bombardier
+1 514 855 8678
Posted on

President Thongloun receives Vietnamese FM Bui Thanh Son

President Thongloun Sisoulith on Apr 28 received a courtesy call from Minister of Foreign Affairs of Vietnam Bui Thanh Son who is on a working visit to Laos between Apr 27-29.

Expressing warm welcome to the Vietnamese minister, President Thongloun described Son’s visit as a significant contribution to strengthening the comprehensive cooperation and longstanding solidarity and mutual assistance between the two fraternal Parties, states and peoples of Laos and Vietnam.

For his part, the Vietnamese minister expressed thanks to the President for his warm welcome and informed him about the outcomes of his talks with his Lao counterpart Saleumxay Kommasith.

Source: Lao News Agency